Skip to main content
STXS logo

Stereotaxis, Inc.

STXSNYSEAMERICANHealthcareMedical Instruments & Supplies

$0.99Today:- (-)1Y −67.81%

As of Oct 26, 2026 close

Market cap
$99.03M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.95$3.15
Volume (live)
-
Avg. volume (3M)
544.46K

Stereotaxis (STXS) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Stereotaxis used $13.69M of cash in operating activities and spent $93.00K on capital expenditures. That left free cash flow of −$13.78M.

Stereotaxis Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Stereotaxis, Inc. (STXS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-21.64-24.05-20.71-18.29-10.72-6.65-4.590.12-5.89
Depreciation & Amortization1.560.970.600.430.110.130.120.580.75
Deferred Income Tax0.000.000.000.000.000.000.00-2.173.84
Stock Based Compensation9.8510.2610.6210.589.363.171.330.560.77
Change in Working Capital-5.622.510.61-1.100.14-2.50-3.82-1.65-4.24
Change in Accounts Receivable-2.020.691.270.32-1.891.81-0.31-0.730.38
Change in Inventory-1.240.68-0.55-2.91-1.14-1.45-0.66-0.370.29
Change in Accounts Payable-0.880.760.22-0.171.43-0.490.370.07-0.97
Change in Other Working Capital0.97-0.100.711.66-0.27-2.56-3.23-0.63-3.94
Other Operating Activities2.171.81-0.26-0.03-1.832.342.340.020.10
Net Cash from Operating Activities-13.69-8.50-9.14-8.42-2.95-3.51-4.62-2.55-4.67
Investing Activities
Capital Expenditures-0.09-0.03-0.37-2.38-1.40-0.07-0.03-0.27-0.08
Acquisitions0.000.110.000.000.000.000.000.000.00
Purchases of Investments0.000.0020.13-19.720.000.000.000.000.00
Sales/Maturities of Investments0.000.0020.130.000.000.000.000.000.00
Other Investing Activities0.000.110.000.000.000.000.000.000.00
Net Cash from Investing Activities-0.090.0719.77-22.09-1.40-0.07-0.03-0.27-0.08
Financing Activities
Debt Repayment0.000.000.000.000.002.160.000.000.00
Common Stock Issued15.660.300.080.220.5515.1824.030.060.04
Other Financing Activities-0.890.00-0.020.000.000.000.009.86-0.10
Net Cash from Financing Activities14.760.300.080.220.5517.3424.039.92-0.06
Summary
Net Change in Cash0.99-8.1310.71-30.29-3.8013.7619.397.11-4.82
Cash at Beginning of Period12.4420.569.8640.1443.9430.1810.803.698.50
Cash at End of Period13.4212.4420.569.8640.1443.9430.1810.803.69
Free Cash Flow-13.78-8.53-9.51-10.79-4.34-3.58-4.65-2.81-4.76

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Stereotaxis Cash Flow

What is Stereotaxis's free cash flow?

Stereotaxis had negative free cash flow of $13.78M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$13.69M minus $93.00K of capital expenditures.

How much does Stereotaxis spend on capital expenditures?

Stereotaxis spent $93.00K on capital expenditures in fiscal 2025, compared with $34.00K a year earlier.

Does Stereotaxis pay dividends or buy back shares?

Stereotaxis's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition